Path ID: DB11750_MESH_D003876_1
Concepts
| Identifier | Name | Type |
|---|---|---|
| MESH:D002990 | Clobetasol | Drug |
| UniProt:P04150 | Glucocorticoid receptor | Protein |
| UniProt:P47712 | Cytosolic phospholipase A2 | Protein |
| GO:0019370 | leukotriene biosynthetic process | BiologicalProcess |
| MESH:D015289 | Leukotrienes | ChemicalSubstance |
| GO:0006954 | inflammatory response | BiologicalProcess |
| HP:0011123 | Inflammatory abnormality of the skin | PhenotypicFeature |
| MESH:D003876 | Dermatitis, Atopic | Disease |
Relationships
NOTE: predicates are annotated in Biolink Model (v1.3.0)
| Subject | Predicate | Object |
|---|---|---|
| Clobetasol | INCREASES ACTIVITY OF | Glucocorticoid Receptor |
| Glucocorticoid Receptor | DECREASES ACTIVITY OF | Cytosolic Phospholipase A2 |
| Cytosolic Phospholipase A2 | POSITIVELY REGULATES | Leukotriene Biosynthetic Process |
| Leukotriene Biosynthetic Process | INCREASES ABUNDANCE OF | Leukotrienes |
| Leukotrienes | POSITIVELY REGULATES | Inflammatory Response |
| Inflammatory Response | POSITIVELY CORRELATED WITH | Inflammatory Abnormality Of The Skin |
| Inflammatory Abnormality Of The Skin | CONTRIBUTES TO | Dermatitis, Atopic |
Comment: Clobetasol is under investigation for the treatment of Scleroderma. Clobetasol propionate is a propionate ester of clobetasol which act as a glucocorticoid receptor and approved for the treatment of dermatoses.
Reference:
- https://go.drugbank.com/drugs/DB11750#mechanism-of-action
- https://go.drugbank.com/drugs/DB01013#mechanism-of-action
- https://en.wikipedia.org/wiki/Clobetasol
- https://www.uniprot.org/uniprot/P04150#function
- https://www.uniprot.org/uniprot/P47712#function
- https://pubmed.ncbi.nlm.nih.gov/11872155/
- https://en.wikipedia.org/wiki/Atopic_dermatitis